Pharmacologic Treatment Options for Obesity: Current and Potential Medications

Abstract

Pharmacotherapy has a role in obesity management when combined with diet, physical activity, and behavior modification. Currently available therapies are safe when used appropriately. New treatments with novel mechanisms of action are likely to be available in the future.

Get full access to this article

View all access options for this article.

References

World Health Organization. Obesity and overweight: fact sheet. Available at: http://www.who.int/hpr/NPH/docs/gs_obesity.pdf. Accessed October 10, 2006.

Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549– 1555.

Preston SH. Deadweight? The influence of obesity on longevity. N Engl J Med. 2005 ;352:1135– 1137.

Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111– 2120.

Fujioka K. Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options. Obes Res. 2002;10(Suppl 2): 116S–123S.

Gray DS, Fujioka K. Use of relative weight and body mass index for the determination of adiposity. J Clin Epidemiol. 1991 ;44:545– 550.

National Institutes of Health. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health;2000 NIH Pub. No. 00–4084.

Meridia. Sibutramine hydrochloride package insert. 2005 Physicians' Desk Reference, 59^th ed. Stamford, CT: Thomson Healthcare; 2004:494– 500.

Xenical. Orlistat package insert. 2005 Physicians' Desk Reference, 59^th ed. Stamford, CT: Thomson Healthcare;2004 : 2951–2955.

10.

Fujioka K. Expert Witness Report on the Appropriate Use of Weight Loss Agents in the Treatment of the Obese Patient. California Medical Board; 1997.

11.

Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005 ;142:532– 546.

12.

Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. BMJ. 1968;1:352– 354.

13.

Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002;26:262– 273.

14.

Bray GA. Contemporary Diagnosis and Management of Obesity and Metabolic Syndrome. Newtown, PA: Handbooks in Health Care Co; 1998.

15.

Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000 ;24:306– 313.

16.

Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160– 167.

17.

James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine trial of obesity reduction and maintenance. Lancet. 2000;356:2119– 2125.

18.

Letter of denial regarding docket #2002P-0120/CP1 and SUP1. Dept of Health and Human services, FDA August 2005 .

19.

Anderson JW, Frank L, Greenway FL, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind placebo-controlled trial. Obes Res. 2002 ;10:633– 641.

20.

Littrell KH, Petty RG, Hiligoss NM, Peabody CD, Johnson CG. Weight loss with topiramate. Ann Pharmacother. 2001 ;35:1141– 1142.

21.

Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition. 2000 ;16:961– 966.

22.

Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003 ;11:722– 733.

23.

Topamax. Topiramate package insert. 2005 Physicians' Desk Reference, 59^th ed. Stamford, CT: Thomson Healthcare; 2004:2541– 2548.

24.

Byetta exenatide injection package insert. October 2006. Available at: http://www.byetta.com. Accessed October 10, 2006.

25.

Symlin pramlintide acetate injection package insert. March 2005. Available at: http://www.symlin.com. Accessed October 10, 2006.

26.

Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69– 72.

27.

Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 2005 ;48:838– 848.

28.

Henry RR, Ratner RE, Stonehouse AH, et al. Exenatide maintained glycemic control with associated weight reduction over 2 years in patients with type 2 diabetes [abstract]. Diabetes. 2006 ;55:A116 .

29.

Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8:436– 447.

30.

Cannon CP. The endocannabinoid system: a new approach to control cardiovascular disease. Clin Cornerstone. 2005 ;7:17– 26.

31.

Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761– 775.

32.

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389– 1397.

33.

Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121– 2134.

34.

Sanofi Aventis. Online news release: Sanofi Aventis, June 21, 2006: European Commission has granted marketing authorisation for ACOMPLIA (rimonabant 20 mg/day) in all 25 European member states.